Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Omer Shvili who wrote (371)	1/4/1999 6:41:00 PM
From: BRAVEHEART	Read Replies (1) of 1386

REQUESTED LINKS, Hi Omer & Company, Does anyone have a link to the newer FDA review process. Also Omer ( or paigow ) you mentioned a recap site with statistics on deals between biotecs & Big Pharma. Could you provide a link for that site. I would be surprised if PARS mgmt would want to incl other products. Given their financial structure and anticipated product revenue I would guess that a partnering of HU211 would be all that is needed at this stage. It depends on mgmt philosophy actually and their growth intentions. They may in fact attempt to partner the other indications to free up their cash for other projects. I personally would rather see them attempt to advance these products on their own to maximize their potential. PS: Just read somewhere that the FDA approval rate is expected to increase from 50 to 80 this year, then level off at 100 per year by 200? ( 1 or 2 ). This fact alone suggests the sector is headed for rapid growth provided the economy stays in balance. BEST WISHES LONE WOLF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next